BIO vs TMDX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 22, 2026

BIO

37.1
AI Score
VS
BIO Wins

TMDX

29.5
AI Score

Investment Advisor Scores

BIO

37score
Recommendation
SELL

TMDX

30score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BIO TMDX Winner
Revenue 1.24B 62.08M BIO
Net Income -155.70M -29.51M TMDX
Gross Margin 52.7% 71.8% TMDX
Net Margin -12.5% -47.5% BIO
Operating Income 106.70M -24.66M BIO
ROE -2.2% -15.7% BIO
ROA -1.5% -10.7% BIO
Total Assets 10.25B 274.87M BIO
Cash 517.00M 204.46M BIO
Debt/Equity 0.17 0.31 BIO
Current Ratio 3.14 12.11 TMDX
Free Cash Flow 144.80M -50.92M BIO

Relative Price Performance (Last 90 Days)

BIO 1M: +20.1% · 3M: +32.5% TMDX 1M: +33.2% · 3M: +37.6%

Current Technical Phase

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.9% over 20 days), RSI 78

RSI (14): 78.2 · Price: $380.03

TMDX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.8% over 20 days), RSI 69

RSI (14): 68.6 · Price: $94.77

Fundamentals Snapshot

Metric BIO TMDX
Market Cap
Forward P/E 37.9 39.4
Trailing P/E 44.4 23.5
Revenue (TTM)
Revenue Growth 0.0% 0.2%
Gross Margin 0.5% 0.6%
Operating Margin 0.1% 0.1%
EPS 8.47 4.00
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.